Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Interpace Biosciences's Enterprise Value is $40.68 Mil.
Interpace Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $4.74 Mil. Therefore, Interpace Biosciences's EV-to-FCF for today is 8.59.
The historical rank and industry rank for Interpace Biosciences's EV-to-FCF or its related term are showing as below:
IDXG'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.05 Med: -1.05 Max: 13.12
Current: 8.59
During the past 13 years, the highest EV-to-FCF of Interpace Biosciences was 13.12. The lowest was -8.05. And the median was -1.05.
IDXG's EV-to-FCF is ranked better than 84.85% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.75
vs IDXG: 8.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Interpace Biosciences's PE Ratio (TTM) for today is calculated as:
Interpace Biosciences's share price for today is $1.525.
Interpace Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's EV-to-FCF falls into.
Interpace Biosciences's current Enterprise Value is $40.68 Mil.
Interpace Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a EV-to-FCF of 8.59 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #15 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Interpace Biosciences' EV-to-FCF too high?
Interpace Biosciences' current EV-to-FCF is 8.59. The Medical Diagnostics & Research industry median EV-to-FCF is 27.75. Interpace Biosciences' value of 8.59 is 69% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #15 out of 99 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' EV-to-FCF compare to PRPO and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #15 out of 99 companies for EV-to-FCF. This places Interpace Biosciences in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 27.75. Interpace Biosciences' value of 8.59 is 69% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.75, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current EV-to-FCF of 8.59 is 69% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current EV-to-FCF is 8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $1.53 — trading 238.9% above its estimated fair value. The current EV-to-FCF is 8.59 and 69% below the Medical Diagnostics & Research industry median of 27.75. Interpace Biosciences' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current EV-to-FCF is 8.59 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.53 is trading 238.9% above its estimated GF Value™ of $0.45.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
EV-to-FCF: 8.59
GF Value™: $0.45 vs. price of $1.53 (238.9% above fair value)
Industry Position: 69% below the Medical Diagnostics & Research median (#15 of 99)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
